NCT07410130Not yet recruiting
Clinical Spectrum and Management of Von Willebrand Disease Among Children in Assiut Governorate
Clinical Spectrum of Von Willebrand Disease Among Children: Frequency, Management, and Outcomes in Assiut Governorate
Source: ClinicalTrials.gov · Last updated 13 Feb 2026
Brief summary (registry, in English)
Von Willebrand disease (VWD) is the most common inherited bleeding disorder in children. It occurs due to a deficiency or dysfunction of von Willebrand factor, a protein that plays an essential role in blood clotting. Children with VWD may experience frequent nosebleeds, easy bruising, prolonged bleeding after injuries or surgeries, and, in adolescent girls, heavy menstrual bleeding. The severity of symptoms varies widely depending on the type of the disease and the level of the clotting factor. Despite its clinical importance, data about the frequency, clinical presentation, and treatment outcomes of von Willebrand disease among children in Upper Egypt are limited. Early recognition and appropriate management are crucial to prevent complications, reduce hospital visits, and improve quality of life. This observational study aims to assess the frequency of von Willebrand disease among children attending Assiut University Children's Hospital, describe the different disease subtypes, and evaluate the clinical bleeding patterns and management strategies used in routine practice. The study will include children aged 0-18 years with suspected or confirmed VWD. Information will be collected from medical records and clinical evaluations, including bleeding symptoms, laboratory test results, disease classification, and treatment approaches. The results of this study are expected to improve understanding of von Willebrand disease in children in this region and support better diagnostic and therapeutic planning for affected patients.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 25 (estimated)
- First submitted
- 29 Jan 2026
- Start date
- Mar 2026
- Primary completion date
- Sept 2026
- Lead sponsor
- Assiut University
- Diseases
- Haemophilia
- NCT number
- NCT07410130
What you commit to
- Study type: Observational
- Planned participants: 25
- From Mar 2026 to the primary completion date, Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other inherited bleeding disorders, such as:
Lab values
- Platelet function disorders.
- Acquired bleeding disorders, including:
- Liver disease.
- Renal insufficiency.
- Vitamin K deficiency.
- Disseminated intravascular coagulation (DIC).
- Use of medications that may interfere with coagulation testing (e.g., anticoagulants, antiplatelet drugs).
- Incomplete clinical or laboratory data (for retrospective cases).
- Refusal of consent for participation (for prospective cases).
Other
- Hemophilia A or B.
- Rare coagulation factor deficiencies (e.g., factors I, V, VII, X, XI deficiency).
Who the study is looking for
- Age 0-18 years.
- Residents of Assiut Governorate or receiving care at Assiut University Children's Hospital.
- Suspected or confirmed von Willebrand disease (VWD) based on clinical bleeding symptoms or referral for evaluation.
- Patients diagnosed with VWD using standard laboratory tests, including:
- VWF antigen (VWF:Ag).
- VWF ristocetin cofactor activity (VWF:RCo).
- Factor VIII activity.
Age in the registry: 0 years to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Assiut University Coordinator of this site? Confirm its status | Asyut | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.